PTGX Q1 2025 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M-88.9% YoY

Gross Profit

$28M100.0% margin

Operating Income

-$19M-68.2% margin

Net Income

-$12M-41.2% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-83.4%

Cash Flow

Operating Cash Flow

$125M

Free Cash Flow

$125M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$742M

Total Liabilities

$53M

Stockholders' Equity

$689M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$255M	-88.9%
Gross Profit	$28M	$255M	-88.9%
Operating Income	-$19M	$206M	-109.4%
Net Income	-$12M	$207M	-105.6%